Major trial tests best way to boost radiation for prostate cancer

NCT ID NCT07426055

Recruiting now Disease control Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 4 times

Summary

This study is testing whether adding a focused radiation boost after standard short-course radiotherapy improves outcomes for men with localized prostate cancer. About 1,200 men will be randomly assigned to receive either standard SBRT alone or SBRT plus one of three boost methods: HDR brachytherapy, LDR brachytherapy, or an extra SBRT dose. The goal is to find which approach best prevents cancer recurrence while limiting side effects on urinary, bowel, and sexual function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (SBRT, HDR brachytherapy, LDR brachytherapy, and external beam radiotherapy)
What this could lead to: If successful, this trial could show which radiation approach best controls prostate cancer while minimizing side effects, helping doctors choose the optimal treatment for future patients.
What could go wrong: This is a large, late-phase trial, but all treatments are already standard—so the benefit may be modest. Long follow-up is needed, and results may not apply to all prostate cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DOSE ESCALATION: SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DOSE ESCALATION: SOLID TUMORS LOCALIZED PROSTATE CANCER PROSTATE BRACHYTHERAPY PROSTATE CANCER (ADENOCARCINOMA) STEREOTACTIC BODY RADIATION THERAPY (SBRT)

Contacts and locations

Locations

Affidea Nu-Med, Center of Oncological Diagnostics and Therapy
RECRUITING

Zamość, Lublin Voivodeship, 22-400, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.